A genetic disorder reveals a hematopoietic stem cell regulatory network co-opted in leukemia

Nat Immunol. 2023 Jan;24(1):69-83. doi: 10.1038/s41590-022-01370-4. Epub 2022 Dec 15.

Abstract

The molecular regulation of human hematopoietic stem cell (HSC) maintenance is therapeutically important, but limitations in experimental systems and interspecies variation have constrained our knowledge of this process. Here, we have studied a rare genetic disorder due to MECOM haploinsufficiency, characterized by an early-onset absence of HSCs in vivo. By generating a faithful model of this disorder in primary human HSCs and coupling functional studies with integrative single-cell genomic analyses, we uncover a key transcriptional network involving hundreds of genes that is required for HSC maintenance. Through our analyses, we nominate cooperating transcriptional regulators and identify how MECOM prevents the CTCF-dependent genome reorganization that occurs as HSCs differentiate. We show that this transcriptional network is co-opted in high-risk leukemias, thereby enabling these cancers to acquire stem cell properties. Collectively, we illuminate a regulatory network necessary for HSC self-renewal through the study of a rare experiment of nature.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Cell Differentiation / genetics
  • Hematopoietic Stem Cells
  • Humans
  • Leukemia* / genetics
  • Neoplasms*
  • Transcription Factors / genetics

Substances

  • Transcription Factors